What the FDA labels say about taking them together
Rifampin and selexipag
Selexipag's FDA label of May 28, 2026 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name selexipag. The selexipag label: “Reduce the dosing of UPTRAVI to once daily. CYP2C8 inducers (e.g., rifampin) decrease exposure to the active metabolite.”
Check it at the source: the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.); the selexipag FDA label on DailyMed (effective May 28, 2026, Actelion Pharmaceuticals US, Inc.).
What does the rifampin label say about selexipag?
Rifampin's label (effective February 11, 2026) does not name selexipag in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
What does the selexipag label say about rifampin?
Selexipag label, drug interactionsReduce the dosing of UPTRAVI to once daily. ( 2.7 , 7.1 , 12.3 ) CYP2C8 inducers (e.g., rifampin) decrease exposure to the active metabolite.
Source: FDA drug label (UPTRAVI), Actelion Pharmaceuticals US, Inc., effective May 28, 2026 (SPL set a7a23b87-f892-4e2c-8e2e-ebf841220f90), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rifampin | Selexipag | |
|---|---|---|
| Labeled for | n/a | Pulmonary arterial hypertension |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.679 per capsule 300 mg capsule | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once